https://www.selleckchem.com/pr....oducts/oxiglutatione
1-51.9), and median progression-free survival was 7.2 months (95 % CI 4.1-7.5). Median overall survival was 17.5 months (95 % CI 10.8-24.3). Most frequent adverse events, regardless of study drug relationship (mostly grade 1/2), were diarrhea (74.8 %), vomiting (62.1 %), alanine transaminase increased (59.2 %), aspartate transaminase increased (58.3 %), and nausea (58.3 %). Ceritinib PK in Chinese patients is consistent with those observed in the global ASCEND-1 study. Ceritinib was well tolerated and showed durable responses in C
Like
Comment
Share
